radioiodine dosage and modality koutsikos
TRANSCRIPT
![Page 1: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/1.jpg)
Radioiodine dosage and modality
John T. Koutsikos, MD, PhDNuclear Medicine Physician
![Page 2: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/2.jpg)
Conflict of Interest
NOTHING TO DECLARE
![Page 3: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/3.jpg)
Introduction
Radioiodine has been used in the management of patients with well-differentiated thyroid cancer since the 1940s.
Saul Hertz
![Page 4: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/4.jpg)
Introduction
Iodine (I-131) causes acute thyroid-cell death by emission of short path-length (1 to 2 mm) beta rays.
I-131 must be taken up by thyroid tissue to be effective.
As a result, it is of no value in patients whose thyroid cancers do not concentrate iodine, i.e. patients with medullary cancer, lymphoma, or anaplastic cancer.
![Page 5: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/5.jpg)
General treatment recommendations
The treatment of choice for patients diagnosed with thyroid cancer is surgery, when possible.
Usually, surgery is followed by treatment with radioiodine and thyroxine therapy.
Generally, radiation therapy and chemotherapy do not have a prominent role in the treatment of thyroid cancer.
![Page 6: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/6.jpg)
Goals of initial therapy of DTC
The basic goals of initial therapy for patients with DTC are to: improve overall and disease-specific survival, reduce the risk of persistent/recurrent disease and
associated morbidity, permit accurate disease staging and risk
stratification, while minimizing treatment-related morbidity and unnecessary
therapy.
![Page 7: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/7.jpg)
Staging and Treatment of DTC
The recommended treatment depends on the stage of
differentiated thyroid cancer and the risk of
recurrence.
This risk varies from very low to high.
The treatment may differ from the general statements,
for reasons related to patients’ individual
circumstances.
![Page 8: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/8.jpg)
Systems of staging / risk evaluation
They are similar to one another but not identical,
indicating our lack of precise long-term outcome
data for all the variables
They remain valuable for prognostic purposes
and in considering therapeutic options.
Using several prognostic fractors such as age,
grade, tumor size, metastasis, etc.
![Page 9: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/9.jpg)
GUIDELINES
![Page 10: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/10.jpg)
Can we rely on staging systems
very much?
![Page 11: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/11.jpg)
Goals of radioiodine administration
![Page 12: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/12.jpg)
2015 ATA guidelines
Post-Surgical RAI Indicated?
![Page 13: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/13.jpg)
2015 ATA guidelines
Post-Surgical RAI Indicated?
![Page 14: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/14.jpg)
Post-Surgical RAI Indicated?
![Page 15: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/15.jpg)
2012SNMMIguidelines
![Page 16: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/16.jpg)
Selection of Activity
![Page 17: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/17.jpg)
2012 SNMMI guidelines
![Page 18: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/18.jpg)
2012 SNMMI guidelines Ablation of thyroid bed remnants
30-100 mCi
Treatment of DTC in the cervical or mediastinal lymph nodes– 150-200 mCi
Treatment of distant metastases– 200 mCi or more
![Page 19: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/19.jpg)
Limited Use Selected Use Definite UseATA low-risk ATA low-
intermediate riskATA high-risk
<45 yrs<2 cm
≥45 yrs≥2cm
Gross invasionResidual disease
No LN or invasion
Positive LN LN invasionDistant mets
No RAI (or 30mCi?)
rhTSH RAI(30-50 mCi)
Wthdr RAI(dosimetry?)
RemnantAblation
Adjuvant Therapy
Therapy
2015 ATA guidelines
![Page 20: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/20.jpg)
ESTIMABL (Fr) and HiLo (UK) studiesN Engl J Med, May 2012
Both randomised studies have shown effective remnant ablation using lower RAI dose (30 mCi)
![Page 21: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/21.jpg)
Low vs High RAI dose for remnant ablation: a Meta-Analysis Cheng W et al, JCEM 98:1353, 2013
9% lower successful ablation rate was identified in low doses than
in high doses, though not reaching any significance (RR, 0.91;
95% CI, 0.79–1.04; P = 0.15).
![Page 22: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/22.jpg)
Clin Nucl Med. 2015 Oct;40(10):774-9.
The rate of complete ablation of high activities was statistically significant higher than that of low
activities (RR, 0.89; 95% CI, 0.81–0.97; P = 0.008)
![Page 23: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/23.jpg)
J Clin Endocrinol Metab 99: 4487– 4496, 2014
1298 DTC patients were included (698 low risk, 434 high risk M0, and 136 M1)
grouped according to ablation activity– I ≤ 54 mCi– II 54 – 81 mCi– III > 81 mCi
subdivided by age ( <45 y and >45 y at diagnosis)
![Page 24: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/24.jpg)
There were no long-term (10-15 year) overall survival or disease-specific survival differences in younger patients (<45 yo) who received lower administered activities of 131I (≤54 mCi) compared with those receiving higher administered activities
The older patients (> 45 yo), however, who received lower administered activities of 131I (≤54 mCi) did have a lower disease-specific survival compared with those receiving higher administered activities.
![Page 25: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/25.jpg)
DTC-specific survival in low-risk patients Recurrence-free survival in high-risk patients
without distant metastases
DTC-specific survival in high-risk pts
without distant metastases
older patients> 45 yo
![Page 26: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/26.jpg)
Fallahi B. et al.Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial.
In the low-dose group, more patients needed a second dose of I-131, resulting in a higher cumulative activity (median, 4810 vs. 3700 MBq, P<0.0001).
The higher dose of I-131 (3700 MBq) resulted in successful ablation more often than the low dose (1110 MBq).
Nucl Med Commun. 2012 Mar;33(3):275-82.
![Page 27: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/27.jpg)
Can we rely on guidelinesvery much?
![Page 28: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/28.jpg)
![Page 29: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/29.jpg)
Radioactive iodine uptake measurements
![Page 30: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/30.jpg)
Neither the ATA or ETA guidelinesrecommend this test
SNMMI
2012
Radioactive iodine uptake measurements
“…, depending on the radioiodine uptakemeasurement and amount of residualfunctioning tissue present”
![Page 31: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/31.jpg)
Case 1
Female, 20 y.o. June 2014 total thyroidectomy (general surgeon) Histology: papillary carcinoma
– 0.9 cm l.l. (diffuse sclerosing) and– 0.5 cm r.l. – 2 ln’s not metastatic
![Page 32: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/32.jpg)
Case 1
I-131? YES What dose? > 100 mCi
![Page 33: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/33.jpg)
Case 1
U/S: no findings (no residual thyroid tissue, no ln’s) TSH 127.8 μIU/ml Tg 19.2 ng/ml Anti-Tg: (-)ve Uptake measurement Yes? No?
![Page 34: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/34.jpg)
Uptake measurement (60 μCi I-131)
Thyroid Uptake = 14,3 %
![Page 35: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/35.jpg)
Next what?
Surgery ?
Low Dose I-131 ?
30 mCi I-131
![Page 36: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/36.jpg)
Post ablation WBS
![Page 37: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/37.jpg)
Follow-up
June 2015 TSH 0.2 μIU/ml Tg < 0.1 ng/ml Anti-Tg: (-)ve U/S: (-)ve WBS (5 mCi I-131) with rh-TSH
![Page 38: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/38.jpg)
WBS (5 mCi I-131)
Tg = 0.2 ng/ml
![Page 39: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/39.jpg)
Guidelines usually are formulated by physicians from international centers of excellence, and may not be fully applicable elsewhere
![Page 40: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/40.jpg)
HOMESWEETHOME
U/S
SurgeonEndocrinologist
![Page 41: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/41.jpg)
Frangos S, Iakovou IP, et. alEur J Nucl Med Mol Imaging. 2015 Dec;42(13):2045-55
“… putatively “low-risk” DTC patients frequently had higher-risk features, or characteristics confounding risk stratification. This finding suggests that outside international centres of excellence, limitations in surgical experience and in histopathology reporting may cast important doubt on such patients’ “low-risk” classification.”
![Page 42: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/42.jpg)
Can we rely on guidelinesvery much?
![Page 43: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/43.jpg)
![Page 44: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/44.jpg)
Part II - Modality
Molecular Marker Status
Low-iodine diet
Hormone withdrawl
rh-TSH
![Page 45: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/45.jpg)
What is the role of molecular marker status in therapeutic RAI decision-making?
Has yet to be established.
Can’t be recommended at this time.
The ESTIMABL2 study will analyze the
relevance of BRAF status on outcome.
![Page 46: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/46.jpg)
Of the 97 T1aN0M0 pts who received post-op RAI, the rate of biochemical persistence of disease (defined by a stimulated thyroglobulin of >1 ng/mL), was 13% in the 39 BRAF positive patients and 1.7% in the BRAF negative patients.
To distinguish those pts who require less or more aggressive treatments.
J Clin Endocrinol Metab. 2012; 97:4390- 4398
![Page 47: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/47.jpg)
Low-iodine diet
The purpose of a low-iodine diet is to
deplete the body of its stores of iodine, to
help increase the effectiveness of the
radioactive iodine
![Page 48: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/48.jpg)
Is a low-iodine diet necessary before remnant ablation?
![Page 49: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/49.jpg)
Dietary Sources of Significant Amounts of Iodine
![Page 50: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/50.jpg)
Pharmaceuticals Blocking Radioiodine Uptake
![Page 51: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/51.jpg)
![Page 52: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/52.jpg)
To withdraw or not to withdraw[To rhTSH or not to rhTSH]
![Page 53: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/53.jpg)
ESTIMABL (Fr) and HiLo (UK) studiesN Engl J Med, May 2012
Both studies have shown equal results either using withdrawal or rhTSH stimulation of RAI uptake
As a result of these studies the use of rhTSH was expanded for the RAI range 30-100 mCi in Europe (Dec 2012)
![Page 54: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/54.jpg)
Recurrence rate in the same subgroups
![Page 55: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/55.jpg)
![Page 56: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/56.jpg)
![Page 57: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/57.jpg)
![Page 58: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/58.jpg)
![Page 59: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/59.jpg)
![Page 60: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/60.jpg)
![Page 61: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/61.jpg)
Take home message
![Page 62: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/62.jpg)
70 years Nuc Med & DTC
![Page 63: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/63.jpg)
![Page 64: Radioiodine dosage and modality koutsikos](https://reader030.vdocuments.mx/reader030/viewer/2022020213/58f03e861a28abcb0d8b45f3/html5/thumbnails/64.jpg)
Thank you!